Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 78
- Registration Number
- NCT06982846
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
- Conditions
- Diabetes MellitusInsulin Sensitivity
- Interventions
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 95
- Registration Number
- NCT06982859
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
- Conditions
- ObesityOverweightType 2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT06972472
- Locations
- 🇺🇸
Southern California Clinical Research, Santa Ana, California, United States
🇺🇸Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States
🇺🇸Norcal Endocrinology & Internal Medicine, San Ramon, California, United States
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 600
- Registration Number
- NCT06972459
- Locations
- 🇺🇸
Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson, Arizona, United States
🇺🇸Norcal Endocrinology & Internal Medicine, San Ramon, California, United States
🇺🇸Southern California Clinical Research, Santa Ana, California, United States
A Study of LY4268989 (MORF-057) in Healthy Participants
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT06964776
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
- Conditions
- Type 1 DiabetesObesityOverweight
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 465
- Registration Number
- NCT06962280
- Locations
- 🇺🇸
Kaiser Permanente Bonita Medical Offices, Bonita, California, United States
🇺🇸AMCR Institute, Escondido, California, United States
🇺🇸Mary & Dick Allen Diabetes Center, Newport Beach, California, United States
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 487
- Registration Number
- NCT06952530
- Locations
- 🇺🇸
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 974
- Registration Number
- NCT06948422
- Locations
- 🇺🇸
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- Conditions
- HypertensionOverweight or Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 487
- Registration Number
- NCT06948435
- Locations
- 🇺🇸
Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸Chase Medical Research, LLC, Waterbury, Connecticut, United States
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
- Conditions
- HealthyOverweightType 2 DiabetesObesity
- Interventions
- Drug: LY4086940Drug: Placebo
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 165
- Registration Number
- NCT06945419
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
🇸🇬Lilly Centre for Clinical Pharmacology, Singapore, Singapore